Department of Cancer Prevention, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
PLoS One. 2010 Nov 12;5(11):e13978. doi: 10.1371/journal.pone.0013978.
The incidence of colorectal cancer (CRC) increases with age and early onset indicates an increased likelihood for genetic predisposition for this disease. The somatic genetics of tumor development in relation to patient age remains mostly unknown. We have examined the mutation status of five known cancer critical genes in relation to age at diagnosis, and compared the genomic complexity of tumors from young patients without known CRC syndromes with those from elderly patients. Among 181 CRC patients, stratified by microsatellite instability status, DNA sequence changes were identified in KRAS (32%), BRAF (16%), PIK3CA (4%), PTEN (14%) and TP53 (51%). In patients younger than 50 years (n = 45), PIK3CA mutations were not observed and TP53 mutations were more frequent than in the older age groups. The total gene mutation index was lowest in tumors from the youngest patients. In contrast, the genome complexity, assessed as copy number aberrations, was highest in tumors from the youngest patients. A comparable number of tumors from young (<50 years) and old patients (>70 years) was quadruple negative for the four predictive gene markers (KRAS-BRAF-PIK3CA-PTEN); however, 16% of young versus only 1% of the old patients had tumor mutations in PTEN/PIK3CA exclusively. This implies that mutation testing for prediction of EGFR treatment response may be restricted to KRAS and BRAF in elderly (>70 years) patients. Distinct genetic differences found in tumors from young and elderly patients, whom are comparable for known clinical and pathological variables, indicate that young patients have a different genetic risk profile for CRC development than older patients.
结直肠癌(CRC)的发病率随年龄增长而增加,发病年龄较早提示其遗传易感性增加。与患者年龄相关的肿瘤发生的体细胞遗传学仍大多未知。我们已经研究了五个已知的癌症关键基因的突变状态与诊断时的年龄之间的关系,并将无已知 CRC 综合征的年轻患者与老年患者的肿瘤的基因组复杂性进行了比较。在 181 名 CRC 患者中,根据微卫星不稳定性状态进行分层,在 KRAS(32%)、BRAF(16%)、PIK3CA(4%)、PTEN(14%)和 TP53(51%)中发现了 DNA 序列变化。在年龄小于 50 岁的患者(n = 45)中,未观察到 PIK3CA 突变,而 TP53 突变的频率高于年龄较大的组。最年轻患者的肿瘤总基因突变指数最低。相比之下,最年轻患者的肿瘤基因组复杂性(评估为拷贝数异常)最高。年轻(<50 岁)和老年(>70 岁)患者的肿瘤数量相当,四个预测基因标志物(KRAS-BRAF-PIK3CA-PTEN)均为四重阴性;然而,年轻患者中有 16%的肿瘤仅存在 PTEN/PIK3CA 突变,而老年患者中只有 1%。这意味着预测 EGFR 治疗反应的突变检测可能仅限于老年(>70 岁)患者的 KRAS 和 BRAF。在年龄较大和较小的患者的肿瘤中发现了明显的遗传差异,这些患者在已知的临床和病理变量方面具有可比性,这表明年轻患者的 CRC 发展遗传风险谱与老年患者不同。
Clin Exp Med. 2024-9-26
Clin Med Insights Oncol. 2024-5-25
Cancers (Basel). 2023-10-12
World J Biol Chem. 2023-3-27
Gastroenterology. 2010-6
Proc Natl Acad Sci U S A. 2010-1-20
J Clin Oncol. 2010-1-25
Semin Oncol. 2009-10
Nat Rev Cancer. 2009-10
Cancer Causes Control. 2009-8-11